Cogstate Limited (ASX: CGS) - Share Price

- Current share price for CGS : $2.750

Cogstate Limited (CGS), an ASX-listed company, is a Company that is engaged in creation, validation and commercialisation of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring and recording of conventional brain health assessments.

CGS General Information ⁺

ASX Code	CGS
Website	N/A
Industry/Sector	Health Care Technology
Market Cap ($M)	467
CGS Share Price	$2.750
Day High	$2.770
Day Low	$2.700
Last Close	$2.750
CGS Share Price Movement	- ( No change )

Prices as at 16:40, 20 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Cogstate Limited (CGS) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
HFResult	2¢	100%	27 Aug 2025	29 Sep 2025	-	-	-

See all dividends from Cogstate Limited (CGS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Cogstate Limited (CGS) price-sensitive announcements

CGS - Cogstate 4Q26 and FY26 Business Update

Cogstate Limited, a global leader in neuroscience endpoint innovation, reported its financ

Cogstate Limited (CGS)
8 Jul 2026 | 8:25 AM

CGS - Cogstate 3Q26 Business Update

Cogstate Limited, a leader in clinical trial endpoint data quality and digital cognitive a

Cogstate Limited (CGS)
8 Apr 2026 | 8:21 AM

CGS - 1H25 Investor Presentation Materials

Cogstate Limited has reported strong financial results for the first half of FY2026, with

Cogstate Limited (CGS)
19 Feb 2026 | 8:10 AM

CGS - Cogstate 1H26 Financial Results

Cogstate Limited reported strong financial results for the first half of fiscal year 2026,

Cogstate Limited (CGS)
19 Feb 2026 | 8:10 AM

Cogstate Limited (CGS) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$467	Notification of cessation of securities - CGS	10 Jul 2026 4:43PM	$2.900	$2.750	fallen by 5.17%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$467	Application for quotation of securities - CGS	10 Jul 2026 4:38PM	$2.900	$2.750	fallen by 5.17%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$467	Cogstate 4Q26 and FY26 Business Update	8 Jul 2026 8:25AM	$2.800	$2.750	fallen by 1.79%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$467	Change in substantial shareholding from AEF	3 Jul 2026 10:43AM	$2.710	$2.750	risen by 1.48%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$467	Investor Insights - Webinar Materials	10 Jun 2026 8:25AM	$2.590	$2.750	risen by 6.18%
Cogstate Limited (CGS) ORDINARY FULLY PAID	Health Care	$467	Notification of cessation of securities - CGS	3 Jun 2026 4:44PM	$2.500	$2.750	risen by 10%

CGS Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	PER	DPS	Yield (%)	Franking (%)
2027F	C2	$11.80	24.30%	23.30	4.20	1.50%	0.0%
2026F	C2	$9.50	6.70%	28.90	3.30	1.20%	0.0%
2025A	$15.49	$8.90	71.50%	13.20	2.00	1.70%	100.0%

CGS Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F
4DMedical Limited (4DX)	$1,919M	0.3304	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Cogstate Limited (CGS)	$464M	0.7148	0.0674	0.2421	30.6742	28.7368	23.1356	0.73%	1.21%	1.53%
Pro Medicus Limited (PME)	$19,547M	0.3919	0.2545	0.2962	169.9455	135.4692	104.5132	0.29%	0.38%	0.49%

CGS Directors

Name	Position	Start Date
Mr Bradley O'Connor	Chief Executive Officer, Managing Director	1 Dec 2005
Mr Martyn Kenneth Myer	Non-Executive Chairman, Non-Executive Director	1 Oct 1999
Mr Darryl Noel Inns	Non-Executive Director	1 May 2026
Ms Ingrid Anne Player	Non-Executive Director	30 Aug 2019
Dr Richard Mohs	Non-Executive Director	20 Jan 2017
Ms Kim Wenn	Non-Executive Director	30 Nov 2020

Cogstate Limited (CGS) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
20 May 2026	WENN, Kim	Buy	Indirect Shares	4,030	$2.507	$10,105.200
15 Dec 2025	WENN, Kim	Buy	Indirect Shares	10,183	$2.186	$22,259.800
31 Oct 2025	O'CONNOR, Bradley	Issued	Related Securities	591,822	$1.770	$1,047,525.940

See all changes in directors' interest & trades for Cogstate Limited (CGS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CGS Management

Name	Position
Darren Watson	Chief Financial Officer
Darren Watson	Chief Financial Officer,Joint Company Secretary
Pam Ventola	Chief Science Officer
David James Franks	Company Secretary
Rachel Colite	Executive Vice President, Clinical Trials

CGS Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cogstate Limited (CGS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
28,567,640 (16.90%)	David Dolby
23,714,566 (14%)	Myer, Martyn Kenneth
17,999,016 (10.70%)	Australian Ethical Investment
14,009,827 (8.30%)	Anacacia Pty Limited

CGS Calendar of Events

Date	Event
18 February 2027	Report (Interim)
21 August 2026	Report (Annual)
21 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us